Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03721705
Other study ID # RenewTM NCP-5-1001
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 12, 2018
Est. completion date March 23, 2021

Study information

Verified date April 2022
Source Renew Research, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Randomized Pivotal Study of RenewTM NCP-5 for the Treatment of Mild Cognitive Impairment due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type is a pivotal, single blind, parallel design, multi-site study intends to examine the efficacy and safety of RenewTM NCP-5 therapy in the treatment of Cognitive Impairment due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type. Subjects will be prospectively randomized to treatment or sham (in a 1:1 ratio) using stratification for Cognitive Impairment due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type, and Cardiovascular Risk (CVR) score at multiple sites. Subjects, ages 55-85, will be consented for 13 months and will receive thirty-five 60-minute RenewTM NCP-5 treatment sessions during a 7-to-12-week initial treatment period, and then transition to a lower frequency maintenance period (twice a week) for a total treatment period of 24 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 190
Est. completion date March 23, 2021
Est. primary completion date March 23, 2021
Accepts healthy volunteers No
Gender All
Age group 55 Years to 85 Years
Eligibility Inclusion Criteria: 1. Be 55-85 years of age at the time of signing the informed consent 2. Be able to provide consent or have legally authorized representative/caregiver who can provide consent 3. Be able to read and write in English or Spanish 4. Have a clinical diagnosis consistent with 2011 National Institute of Aging - Alzheimer's Association (NIA-AA) "core clinical criteria" guidelines for: (i) The diagnosis of dementia due to Alzheimer's disease or (ii) The diagnosis of mild cognitive impairment due to Alzheimer's disease: - Montreal Cognitive Assessment (MOCA) score of greater than or equal to 11 - All required checkboxes within the study checklist for "The diagnosis of probable AD dementia" must be "yes" or - All required checkboxes within the study checklist for "The diagnosis of mild cognitive impairment due to Alzheimer's disease" must be "yes" 5. Stable medications for past 30 days and plan to remain on stable medications for the first 24 weeks of study participation for treatment of chronic conditions. 6. Subject should have a caregiver, study partner or companion (which can be a domestic party) and may conduct the assessment over the phone if they don't accompany the participant). 7. Must have the potential to improve by at least 2 points or more in the Vascular Dementia Assessment Scale cognitive subscale (vADAS-COG) Exclusion Criteria: 1. Unwilling or unable to participate in study procedures 2. Weight >297 lbs. or >135 kg at screening 3. Major confounding neurodegenerative or psychiatric disorder unrelated to the condition under study, including: 1. History of clinically-evident stroke 2. Current uncontrolled epileptic seizures or epilepsy 3. Multiple Sclerosis or Parkinson's Disease 4. Current clinically significant major psychiatric disorder (e.g., Major Depressive Disorder) according to the Fifth Edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria or significant psychiatric symptoms (e.g., hallucinations) that could impair the completion of the study 4. Anyone with active or history of cerebral hemorrhage including subdural & subarachnoid or cerebral aneurysm 5. Evidence of any of the following (based on Section 4.1.1(D) of the 2011 NIA-AA guidelines on The diagnosis of dementia due to Alzheimer's disease): 1. Substantial concomitant cerebrovascular disease, defined by a history of a stroke temporally related to the onset or worsening of cognitive impairment; or the presence of multiple or extensive infarcts or severe white matter hyperintensity burden 2. Core features of Dementia with Lewy bodies other than dementia itself 3. Prominent features of behavioral variant frontotemporal dementia 4. Prominent features of semantic variant primary progressive aphasia or nonfluent/agrammatic variant primary progressive aphasia 5. Evidence for another concurrent, active neurological disease, non-neurological medical comorbidity or use of medication that could have a substantial effect on cognition 6. In the opinion of the investigator, any current clinically-significant systemic illness or medical condition that is likely to result in deterioration of the subject's condition, affect the subject's safety during the study, or to be incompatible with performance of the study procedures, including: 1. History of head trauma with a diagnosis of moderate to severe traumatic brain injury 2. Known current substantially elevated intracranial pressure 3. Known current significant sleep deprivation 4. Known history (within five years) or current significant drug abuse or alcoholism 7. Any contraindication for MRI such as insulin pumps or pacemakers, including dual chamber pacemakers where atrial pacing may interfere with RenewTM NCP-5 inflation timing sequence 8. Hypotension as defined as <80/50 blood pressure at the time of screening 9. Ongoing uncontrolled severe hypertension (= 180 mmHg systolic or = 110 mmHg diastolic 10. Heart rates < 35 or >125 beats per minute (BPM) at screening 11. Current uncontrolled arrhythmia. Controlled arrhythmia should have beat-to-beat, cycle-length variability less than ±25% at rest. 12. Current congestive heart failure 13. Cardiac catheterization within two weeks, any surgical intervention within six weeks before RenewTM NCP-5 treatment or a hip or knee replacement within 3 months as long as rehab is complete and symptoms have resolved. 14. Known presence of abdominal aortic aneurysm 15. Existing aortic insufficiency grade II or higher (regurgitation can prevent diastolic augmentation) 16. Current or past venous thrombosis or thromboembolism 17. Current limiting peripheral vascular disease with history strongly suggestive of lower extremity ischemia or claudication, arterial occlusive disease (aortoiliac, ileofemoral, or femoral popliteal) 18. Demonstrable deficiency in sensation in lower extremities as a result of diabetes or other medical condition 19. Current bleeding disorders. 20. Current use of major anti-coagulation therapy (such as Heparin therapy or Coumadin® therapy) with International Normalized Ratio (INR) > 1.5 21. Current severe pulmonary disease that prevents the subject from lying supine 22. Presence of local infection, vasculitis, burn, open wound, or bone fracture on any limb which would prevent the ability to perform the RenewTM NCP-5 treatment 23. Current use of medications that in the investigator's judgement are incompatible with the study goals 24. Significant changes in existing medical plans for treatment of cognitive impairment or dementia in last three months and/or or planned changes during the trial 25. Presence of any of the contraindications for using the RenewTM NCP-5 device 26. Athletic injuries, including Charley horses, pulled muscles and/or edematous muscles; necrotizing cellulitis in the past 30 days which would prevent the ability to perform the RenewTM NCP-5 treatment (evaluate and treat prior to RenewTM NCP-5 treatment) 27. Unwilling or unable to maintain stable exercise regimen throughout the trial 28. Participation in any clinical drug trial 30 days or five half-lives, whichever is longer, prior to screening visit 29. Use of any device to increase cerebral blood flow in the past 30 days. 30. History of claustrophobia. 31. Subject unable to lay supine for 90 minutes

Study Design


Intervention

Device:
Renew NCP-5
Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.

Locations

Country Name City State
Ireland St. James's Hospital Dublin
Singapore National University Hospital Singapore
United States iResearch Atlanta Atlanta Georgia
United States Cardiovascular Advantages, LLC Baton Rouge Louisiana
United States Northwest Clinical Research Center Bellevue Washington
United States Neuro-Behavioral Clinical Research Canton Ohio
United States Irvine Clinical Research Irvine California
United States University of Kansas Medical Center Kansas City Kansas
United States Charter Research Lady Lake Florida
United States Miami Dade Medical Research Institute Miami Florida
United States Xenoscience Phoenix Arizona
United States iResearch Savannah Savannah Georgia

Sponsors (3)

Lead Sponsor Collaborator
Renew Research, LLC ClinEdge, LLC, Navitas Clinical Research, Inc

Countries where clinical trial is conducted

United States,  Ireland,  Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Change From Baseline to 24 Weeks in Vascular Dementia Assessment Scale Cognitive Subscale (vADAS-cog) Using the Average of Scores at 12, 18 and 24 Weeks. The vADAS-cog assessment includes 17 subscale scores. The total score is the sum of all scaled scored from 0-120. The higher values represent more cognitive impairment. The change in vADAS-cog scores from baseline at the timepoints of 12, 18, and 24 weeks is averaged together for each patient. The primary outcome measure is the average of those values for all patients in a group. 24 weeks
Secondary Number of Participants With Treatment Related Adverse Events as Assessed by MedDRA. 24 weeks
Secondary Number of Participants With Treatment Related Serious Adverse Events as Assessed by MedDRA. 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A